Simulations Plus, Inc. (SLP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 42 | 46 | 54 | 60 | 70 | 79 | 82 | 82 |
| Operating profit | $m | -71 | - | ||||||
| Net profit | $m | 9 | 10 | 12 | 10 | 10 | -65 | - | 18 |
| EPS reported | $ | -3.22 | 0.40 | ||||||
| Operating cashflow per share | $ | 0.90 | 1.31 | ||||||
| Capex per share | $ | 0.04 | 0.02 | ||||||
| FCF per share | $ | 0.87 | 1.29 | ||||||
| Free cash flow | $m | 17 | 26 | ||||||
| Net debt | $m | -32 | -50 | ||||||
| Book value equity | $m | 125 | 139 | ||||||
| Book value per share | $ | 6.21 | 6.87 | ||||||
| Number of shares | m | 20.1 | 20.23 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 46.25 | ||||||
| P/B LTM | x | 2.28 | 2.05 | ||||||
| P/S LTM | x | 3.60 | 3.47 | ||||||
| P/FCF LTM | x | 16.36 | 10.92 | ||||||
| EV/EBITDA LTM | x | 17.32 | 19.46 | ||||||
| EV/Sales LTM | x | 3.22 | 4.10 | ||||||
| Earnings Yield LTM | % | -22.72% | +2.16% | ||||||
| FCF Yield | % | +6.11% | +9.15% | ||||||
| Quality | |||||||||
| ROE | % | -51.86% | +6.18% | ||||||
| ROIC | % | -52.61% | +5.32% | ||||||
| Operating margin | % | -89.33% | +14.02% | ||||||
| Gross margin | % | +58.38% | +63.38% | ||||||
| FCF/Sales | % | +21.99% | +31.78% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +13.09% | +17.20% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +36.53% | +104.45% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 28.27 | 53.54 | ||||||
| Net Debt/EBITDA | x | -2.06 | -2.66 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.07% | +0.10% | ||||||
| Net debt/Equity | x | -0.26 | -0.36 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free